ADC Ther­a­peu­tics signs pact with Freenome; Shang­hai Hen­lius Biotech eyes $600M for Hong Kong IPO

→ ADC Ther­a­peu­tics, which last month closed its mon­ster $303 mil­lion E round, is join­ing forces with Freenome, a biotech de­vel­op­ing a di­ag­nos­tic for ear­ly can­cer de­tec­tion through a rou­tine blood draw. ADC will use Freenome’s plat­form to iden­ti­fy pa­tients who are most like­ly to re­spond to treat­ment with its ex­per­i­men­tal drug, lon­cas­tux­imab tesirine, which is cur­rent­ly in a piv­otal Phase II in pa­tients with re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma. ADC hopes to file for an ap­proval in the sec­ond half of 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER